우울증 환자 수 분석과 예측(2026-2035년)

Global Depression Patient Population Analysis is projected to register a strong CAGR during the forecast period (2026-2035).

The global depression patient population continues to expand, reflecting the growing burden of mental health disorders across developed and emerging economies. Depression remains one of the most prevalent psychiatric conditions worldwide and is a leading cause of disability, reduced productivity, and diminished quality of life. The patient population analysis market provides comprehensive insights into disease prevalence, incidence, diagnosed and treated populations, demographic trends, disease severity, treatment patterns, and future epidemiological projections. These analyses support pharmaceutical companies, healthcare providers, research organizations, policymakers, and investors in planning clinical development, commercial strategies, healthcare resource allocation, and patient access initiatives.

The increasing prevalence of depression is being driven by multiple demographic, socioeconomic, and lifestyle factors. Population growth, aging populations, urbanization, economic uncertainty, chronic illnesses, substance abuse, social isolation, and heightened awareness of mental health are contributing to a larger diagnosed patient pool. Improvements in screening programs, primary care diagnosis, and mental health education have also increased the identification of previously undiagnosed patients, expanding the addressable treatment population. Global epidemiological studies continue to demonstrate that women experience depression at significantly higher rates than men, while disease burden increases substantially among older adults and vulnerable populations.

Patient population analysis has become increasingly important as pharmaceutical companies develop targeted therapies for major depressive disorder, treatment-resistant depression, postpartum depression, adolescent depression, and geriatric depression. Detailed epidemiological assessments help organizations identify underserved patient groups, estimate commercial opportunities, optimize clinical trial recruitment, and forecast future treatment demand. As precision psychiatry and biomarker-guided treatment approaches continue to evolve, patient segmentation based on disease subtype, severity, genetics, comorbidities, and treatment response is becoming an essential component of market planning.

The growing adoption of electronic health records, real-world evidence, artificial intelligence, and advanced healthcare analytics is improving the accuracy of patient population studies. These technologies enable researchers to evaluate longitudinal disease progression, healthcare utilization, treatment adherence, and regional disease variations using large-scale clinical datasets. Combined with increasing investment in mental healthcare infrastructure and global mental health initiatives, these developments are expected to support continued expansion of depression patient population analysis throughout the forecast period.

Market Drivers

Rising Global Prevalence of Depression

Depression continues to affect a growing number of individuals worldwide and remains one of the leading contributors to disability. Population growth, increasing life expectancy, and greater recognition of mental health disorders are contributing to continuous expansion of the diagnosed patient population.

Growing awareness among healthcare professionals and the general public is improving diagnosis rates and encouraging earlier intervention.

Improved Mental Health Screening

Healthcare systems are increasingly implementing standardized mental health screening programs within primary care and specialty settings. Early diagnosis initiatives enable identification of depression across diverse patient populations, including adolescents, older adults, and individuals with chronic medical conditions.

Improved screening contributes to more accurate epidemiological assessments and expanded treatment access.

Expansion of Real-World Data Analytics

Electronic medical records, healthcare databases, insurance claims, patient registries, and digital health platforms are providing valuable epidemiological information for patient population analysis.

Advanced analytics improve understanding of disease prevalence, treatment patterns, healthcare utilization, and long-term clinical outcomes.

Increasing Investment in Mental Health Research

Governments, healthcare organizations, pharmaceutical companies, and academic institutions continue expanding investments in depression research and epidemiological studies.

These investments improve disease surveillance, patient registries, and population-based healthcare planning while supporting development of innovative therapies.

Growing Focus on Precision Psychiatry

The transition toward personalized mental healthcare is increasing demand for detailed patient segmentation. Researchers are analyzing clinical characteristics, biomarkers, genetic profiles, disease severity, and treatment response patterns to improve individualized treatment strategies.

Comprehensive patient population analysis supports precision medicine initiatives and future therapeutic development.

Market Restraints

Underdiagnosis of Depression

A substantial proportion of individuals experiencing depression remain undiagnosed due to social stigma, limited healthcare access, and inadequate mental health awareness.

Undiagnosed patients create uncertainty in epidemiological estimates and may reduce the accuracy of patient population forecasting.

Variability in Diagnostic Criteria

Differences in diagnostic practices, screening methodologies, reporting systems, and healthcare accessibility across countries can influence prevalence estimates.

These variations may complicate direct comparison of epidemiological data between regions.

Limited Mental Health Infrastructure

Many low-income and middle-income countries continue to experience shortages of mental health professionals, psychiatric facilities, and diagnostic resources.

Limited healthcare infrastructure may result in incomplete patient identification and underestimation of the true disease burden.

Technology and Segment Insights

By Disease Type

Major depressive disorder represents the largest patient population segment due to its high global prevalence and significant impact on public health.

Treatment-resistant depression represents an increasingly important subgroup as clinicians seek alternative therapies for patients who do not achieve adequate responses to conventional antidepressants.

Additional patient population analyses include persistent depressive disorder, postpartum depression, bipolar depression, seasonal affective disorder, and adolescent depression.

By Patient Demographics

Adults account for the largest proportion of diagnosed depression patients globally. Working-age populations experience significant disease burden due to occupational stress, chronic illnesses, and socioeconomic pressures.

Older adults represent one of the fastest-growing patient segments as aging populations increase worldwide. Depression among elderly individuals is frequently associated with chronic diseases, cognitive decline, and social isolation.

Women continue to exhibit higher prevalence rates than men across most geographic regions, while adolescent and young adult populations are experiencing increasing diagnosis rates.

By Severity

Patients with mild and moderate depression comprise a substantial proportion of the diagnosed population and are commonly managed through pharmacological treatment, psychotherapy, or combined therapeutic approaches.

Severe depression, including treatment-resistant cases, accounts for a smaller but clinically significant segment requiring specialized psychiatric care, advanced pharmacotherapy, neuromodulation, or inpatient management.

By End User

Pharmaceutical companies represent the largest users of depression patient population analysis due to their need for epidemiological data supporting clinical development, commercial forecasting, and market access strategies.

Healthcare providers utilize patient population studies to optimize treatment planning and healthcare resource allocation.

Academic institutions, government agencies, research organizations, and healthcare consulting firms also rely extensively on epidemiological analyses to guide policy development and scientific research.

Regional Insights

North America represents the largest market for depression patient population analysis due to advanced healthcare infrastructure, comprehensive electronic health record systems, strong mental health awareness, and extensive epidemiological research capabilities. High diagnosis rates and broad access to psychiatric services contribute to detailed patient population assessments.

Europe maintains a significant position through well-established healthcare systems, national disease registries, and expanding mental health surveillance programs. Increasing investment in psychiatric research and personalized medicine supports continued market growth.

Asia Pacific is expected to experience the fastest growth during the forecast period. Rising mental health awareness, expanding healthcare infrastructure, increasing diagnosis rates, and growing adoption of digital healthcare technologies are strengthening epidemiological research across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving mental healthcare access through healthcare modernization initiatives, expanded screening programs, and increased government investment in behavioral health services.

Competitive and Strategic Outlook

The global depression patient population analysis market is supported by epidemiology research organizations, healthcare analytics providers, pharmaceutical consulting firms, contract research organizations, and real-world evidence specialists. Competition is increasingly centered on delivering comprehensive epidemiological intelligence that supports strategic planning throughout the pharmaceutical development lifecycle.

Organizations are investing in artificial intelligence, predictive analytics, healthcare databases, electronic medical records integration, and real-world evidence platforms to improve the accuracy and depth of patient population analyses. Strategic collaborations between pharmaceutical companies, healthcare providers, academic institutions, and public health agencies continue to strengthen data availability and analytical capabilities.

Future market development is expected to focus on precision epidemiology, biomarker-based patient segmentation, longitudinal disease monitoring, and advanced forecasting models that support personalized medicine and targeted therapeutic development.

Conclusion

The global depression patient population analysis market is expected to expand steadily as the worldwide burden of depressive disorders continues to increase. Rising disease prevalence, improving diagnostic capabilities, growing mental health awareness, and expanding use of real-world healthcare data are expected to drive demand for comprehensive epidemiological intelligence. Although challenges related to underdiagnosis, regional variability, and healthcare access remain, advances in healthcare analytics, digital technologies, and precision psychiatry will continue to enhance patient population analysis and support strategic decision-making across the global depression treatment landscape.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Global Patient Population Overview
• 1.4 Epidemiology Highlights
• 1.5 Disease Burden Assessment
• 1.6 Key Growth Trends
• 1.7 Strategic Insights
• 1.8 Future Outlook (2025-2045)

2. Disease Overview

• 2.1 Introduction to Depression
• 2.2 Disease Definition and Classification
  • 2.2.1 Major Depressive Disorder (MDD)
  • 2.2.2 Treatment-Resistant Depression (TRD)
  • 2.2.3 Persistent Depressive Disorder (Dysthymia)
  • 2.2.4 Postpartum Depression
  • 2.2.5 Seasonal Affective Disorder
  • 2.2.6 Adolescent Depression
  • 2.2.7 Geriatric Depression
• 2.3 Disease Pathophysiology
• 2.4 Risk Factors and Comorbidities
• 2.5 Disease Burden and Socioeconomic Impact
• 2.6 Diagnostic Pathway Analysis
• 2.7 Challenges in Diagnosis and Treatment

3. Research Methodology and Epidemiology Assumptions

• 3.1 Study Methodology
• 3.2 Data Collection Framework
• 3.3 Epidemiology Modeling Approach
• 3.4 Patient Population Forecasting Methodology
• 3.5 Data Validation and Triangulation
• 3.6 Key Assumptions and Limitations

4. Global Depression Epidemiology Overview

• 4.1 Global Patient Population Overview
• 4.2 Global Prevalence Analysis (2025-2045)
• 4.3 Global Incidence Analysis (2025-2045)
• 4.4 Diagnosed Patient Population Analysis
• 4.5 Treated Patient Population Analysis
• 4.6 Disease Severity Assessment
• 4.7 Epidemiology Forecast Analysis

5. Patient Population Segmentation

• 5.1 By Disease Type
  • 5.1.1 Major Depressive Disorder (MDD)
  • 5.1.2 Treatment-Resistant Depression (TRD)
  • 5.1.3 Persistent Depressive Disorder (Dysthymia)
  • 5.1.4 Postpartum Depression
  • 5.1.5 Seasonal Affective Disorder
  • 5.1.6 Adolescent Depression
  • 5.1.7 Geriatric Depression
• 5.2 By Disease Severity
  • 5.2.1 Mild Depression
  • 5.2.2 Moderate Depression
  • 5.2.3 Severe Depression
• 5.3 By Gender
  • 5.3.1 Male Population
  • 5.3.2 Female Population
• 5.4 By Age Group
  • 5.4.1 Pediatric Population (<18 Years)
  • 5.4.2 Young Adults (18-24 Years)
  • 5.4.3 Adults (25-44 Years)
  • 5.4.4 Middle-Aged Population (45-64 Years)
  • 5.4.5 Elderly Population (?65 Years)
• 5.5 By Treatment Status
  • 5.5.1 Diagnosed Patients
  • 5.5.2 Undiagnosed Patients
  • 5.5.3 Treated Patients
  • 5.5.4 Untreated Patients
• 5.6 By Care Setting
  • 5.6.1 Primary Care Settings
  • 5.6.2 Specialty Mental Health Centers
  • 5.6.3 Hospital-Based Care
  • 5.6.4 Community Mental Health Services

6. Epidemiological Trends and Disease Burden

• 6.1 Historical Epidemiology Trends
• 6.2 Disease Burden Analysis
• 6.3 Disability and Quality-of-Life Impact
• 6.4 Mortality and Suicide Risk Assessment
• 6.5 Comorbidity Analysis
• 6.6 Healthcare Resource Utilization
• 6.7 Future Epidemiological Trends

7. Diagnosed and Treated Population Analysis

• 7.1 Diagnosis Rate Assessment
• 7.2 Screening and Detection Trends
• 7.3 Treatment-Seeking Behavior Analysis
• 7.4 Treatment Coverage Assessment
• 7.5 Treatment Gap Analysis
• 7.6 Access to Mental Health Services
• 7.7 Future Diagnosis and Treatment Trends

8. Unmet Needs and Population Challenges

• 8.1 Diagnostic Challenges
• 8.2 Access-to-Care Barriers
• 8.3 Treatment Adherence Challenges
• 8.4 Regional Variability Assessment
• 8.5 Health Equity Considerations
• 8.6 Future Opportunities for Early Diagnosis

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Total Prevalence
  • 9.1.2 Total Incidence
  • 9.1.3 Diagnosed Patient Population
  • 9.1.4 Disease Type Distribution
  • 9.1.5 Age-Specific Epidemiology
  • 9.1.6 Gender-Specific Epidemiology
  • 9.1.7 Forecast Analysis (2025-2045)
• 9.2 Europe
  • 9.2.1 Total Prevalence
  • 9.2.2 Total Incidence
  • 9.2.3 Diagnosed Patient Population
  • 9.2.4 Disease Type Distribution
  • 9.2.5 Age-Specific Epidemiology
  • 9.2.6 Gender-Specific Epidemiology
  • 9.2.7 Forecast Analysis (2025-2045)
• 9.3 Asia-Pacific
  • 9.3.1 Total Prevalence
  • 9.3.2 Total Incidence
  • 9.3.3 Diagnosed Patient Population
  • 9.3.4 Disease Type Distribution
  • 9.3.5 Age-Specific Epidemiology
  • 9.3.6 Gender-Specific Epidemiology
  • 9.3.7 Forecast Analysis (2025-2045)
• 9.4 Latin America
  • 9.4.1 Total Prevalence
  • 9.4.2 Total Incidence
  • 9.4.3 Diagnosed Patient Population
  • 9.4.4 Disease Type Distribution
  • 9.4.5 Age-Specific Epidemiology
  • 9.4.6 Gender-Specific Epidemiology
  • 9.4.7 Forecast Analysis (2025-2045)
• 9.5 Middle East & Africa
  • 9.5.1 Total Prevalence
  • 9.5.2 Total Incidence
  • 9.5.3 Diagnosed Patient Population
  • 9.5.4 Disease Type Distribution
  • 9.5.5 Age-Specific Epidemiology
  • 9.5.6 Gender-Specific Epidemiology
  • 9.5.7 Forecast Analysis (2025-2045)

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Total Prevalence
  • 10.1.2 Total Incidence
  • 10.1.3 Diagnosed Cases
  • 10.1.4 Disease Type Distribution
  • 10.1.5 Age-Specific Epidemiology
  • 10.1.6 Gender-Specific Epidemiology
  • 10.1.7 Forecast Analysis (2025-2045)
• 10.2 Canada
  • 10.2.1 Total Prevalence
  • 10.2.2 Total Incidence
  • 10.2.3 Diagnosed Cases
  • 10.2.4 Disease Type Distribution
  • 10.2.5 Age-Specific Epidemiology
  • 10.2.6 Gender-Specific Epidemiology
  • 10.2.7 Forecast Analysis (2025-2045)
• 10.3 Germany
  • 10.3.1 Total Prevalence
  • 10.3.2 Total Incidence
  • 10.3.3 Diagnosed Cases
  • 10.3.4 Disease Type Distribution
  • 10.3.5 Age-Specific Epidemiology
  • 10.3.6 Gender-Specific Epidemiology
  • 10.3.7 Forecast Analysis (2025-2045)
• 10.4 United Kingdom
  • 10.4.1 Total Prevalence
  • 10.4.2 Total Incidence
  • 10.4.3 Diagnosed Cases
  • 10.4.4 Disease Type Distribution
  • 10.4.5 Age-Specific Epidemiology
  • 10.4.6 Gender-Specific Epidemiology
  • 10.4.7 Forecast Analysis (2025-2045)
• 10.5 France
  • 10.5.1 Total Prevalence
  • 10.5.2 Total Incidence
  • 10.5.3 Diagnosed Cases
  • 10.5.4 Disease Type Distribution
  • 10.5.5 Age-Specific Epidemiology
  • 10.5.6 Gender-Specific Epidemiology
  • 10.5.7 Forecast Analysis (2025-2045)
• 10.6 Italy
  • 10.6.1 Total Prevalence
  • 10.6.2 Total Incidence
  • 10.6.3 Diagnosed Cases
  • 10.6.4 Disease Type Distribution
  • 10.6.5 Age-Specific Epidemiology
  • 10.6.6 Gender-Specific Epidemiology
  • 10.6.7 Forecast Analysis (2025-2045)
• 10.7 Spain
  • 10.7.1 Total Prevalence
  • 10.7.2 Total Incidence
  • 10.7.3 Diagnosed Cases
  • 10.7.4 Disease Type Distribution
  • 10.7.5 Age-Specific Epidemiology
  • 10.7.6 Gender-Specific Epidemiology
  • 10.7.7 Forecast Analysis (2025-2045)
• 10.8 China
  • 10.8.1 Total Prevalence
  • 10.8.2 Total Incidence
  • 10.8.3 Diagnosed Cases
  • 10.8.4 Disease Type Distribution
  • 10.8.5 Age-Specific Epidemiology
  • 10.8.6 Gender-Specific Epidemiology
  • 10.8.7 Forecast Analysis (2025-2045)
• 10.9 Japan
  • 10.9.1 Total Prevalence
  • 10.9.2 Total Incidence
  • 10.9.3 Diagnosed Cases
  • 10.9.4 Disease Type Distribution
  • 10.9.5 Age-Specific Epidemiology
  • 10.9.6 Gender-Specific Epidemiology
  • 10.9.7 Forecast Analysis (2025-2045)
• 10.10 India
  • 10.10.1 Total Prevalence
  • 10.10.2 Total Incidence
  • 10.10.3 Diagnosed Cases
  • 10.10.4 Disease Type Distribution
  • 10.10.5 Age-Specific Epidemiology
  • 10.10.6 Gender-Specific Epidemiology
  • 10.10.7 Forecast Analysis (2025-2045)
• 10.11 South Korea
  • 10.11.1 Total Prevalence
  • 10.11.2 Total Incidence
  • 10.11.3 Diagnosed Cases
  • 10.11.4 Disease Type Distribution
  • 10.11.5 Age-Specific Epidemiology
  • 10.11.6 Gender-Specific Epidemiology
  • 10.11.7 Forecast Analysis (2025-2045)
• 10.12 Australia
  • 10.12.1 Total Prevalence
  • 10.12.2 Total Incidence
  • 10.12.3 Diagnosed Cases
  • 10.12.4 Disease Type Distribution
  • 10.12.5 Age-Specific Epidemiology
  • 10.12.6 Gender-Specific Epidemiology
  • 10.12.7 Forecast Analysis (2025-2045)

11. Competitive Landscape

• 11.1 Epidemiology Data Providers Overview
• 11.2 Mental Health Research Organizations
• 11.3 Disease Awareness Initiatives
• 11.4 Screening and Diagnostic Programs
• 11.5 Patient Registry Landscape
• 11.6 Population Health Management Trends

12. Company Profiles

• 12.1 Johnson & Johnson
  • 12.1.1 Overview
  • 12.1.2 Financials
  • 12.1.3 Depression Portfolio Overview
  • 12.1.4 Epidemiology-Based Commercial Strategy
  • 12.1.5 Target Patient Population Focus
  • 12.1.6 Market Expansion Strategy
  • 12.1.7 Strategic Initiatives
  • 12.1.8 Recent Developments
• 12.2 AbbVie Inc.
  • 12.2.1 Overview
  • 12.2.2 Financials
  • 12.2.3 Depression Portfolio Overview
  • 12.2.4 Epidemiology-Based Commercial Strategy
  • 12.2.5 Target Patient Population Focus
  • 12.2.6 Market Expansion Strategy
  • 12.2.7 Strategic Initiatives
  • 12.2.8 Recent Developments
• 12.3 Sage Therapeutics, Inc.
  • 12.3.1 Overview
  • 12.3.2 Financials
  • 12.3.3 Depression Portfolio Overview
  • 12.3.4 Epidemiology-Based Commercial Strategy
  • 12.3.5 Target Patient Population Focus
  • 12.3.6 Market Expansion Strategy
  • 12.3.7 Strategic Initiatives
  • 12.3.8 Recent Developments
• 12.4 Otsuka Pharmaceutical Co., Ltd.
  • 12.4.1 Overview
  • 12.4.2 Financials
  • 12.4.3 Depression Portfolio Overview
  • 12.4.4 Epidemiology-Based Commercial Strategy
  • 12.4.5 Target Patient Population Focus
  • 12.4.6 Market Expansion Strategy
  • 12.4.7 Strategic Initiatives
  • 12.4.8 Recent Developments
• 12.5 Lundbeck A/S
  • 12.5.1 Overview
  • 12.5.2 Financials
  • 12.5.3 Depression Portfolio Overview
  • 12.5.4 Epidemiology-Based Commercial Strategy
  • 12.5.5 Target Patient Population Focus
  • 12.5.6 Market Expansion Strategy
  • 12.5.7 Strategic Initiatives
  • 12.5.8 Recent Developments
• 12.6 Takeda Pharmaceutical Company Limited
  • 12.6.1 Overview
  • 12.6.2 Financials
  • 12.6.3 Depression Portfolio Overview
  • 12.6.4 Epidemiology-Based Commercial Strategy
  • 12.6.5 Target Patient Population Focus
  • 12.6.6 Market Expansion Strategy
  • 12.6.7 Strategic Initiatives
  • 12.6.8 Recent Developments
• 12.7 Neurocrine Biosciences, Inc.
  • 12.7.1 Overview
  • 12.7.2 Financials
  • 12.7.3 Depression Portfolio Overview
  • 12.7.4 Epidemiology-Based Commercial Strategy
  • 12.7.5 Target Patient Population Focus
  • 12.7.6 Market Expansion Strategy
  • 12.7.7 Strategic Initiatives
  • 12.7.8 Recent Developments
• 12.8 Biogen Inc.
  • 12.8.1 Overview
  • 12.8.2 Financials
  • 12.8.3 Depression Portfolio Overview
  • 12.8.4 Epidemiology-Based Commercial Strategy
  • 12.8.5 Target Patient Population Focus
  • 12.8.6 Market Expansion Strategy
  • 12.8.7 Strategic Initiatives
  • 12.8.8 Recent Developments
• 12.9 Compass Pathways plc
  • 12.9.1 Overview
  • 12.9.2 Financials
  • 12.9.3 Depression Portfolio Overview
  • 12.9.4 Epidemiology-Based Commercial Strategy
  • 12.9.5 Target Patient Population Focus
  • 12.9.6 Market Expansion Strategy
  • 12.9.7 Strategic Initiatives
  • 12.9.8 Recent Developments
• 12.10 Alto Neuroscience, Inc.
  • 12.10.1 Overview
  • 12.10.2 Financials
  • 12.10.3 Depression Portfolio Overview
  • 12.10.4 Epidemiology-Based Commercial Strategy
  • 12.10.5 Target Patient Population Focus
  • 12.10.6 Market Expansion Strategy
  • 12.10.7 Strategic Initiatives
  • 12.10.8 Recent Developments

13. Future Outlook and Strategic Recommendations

• 13.1 Future Epidemiology Trends
• 13.2 Disease Burden Outlook
• 13.3 Diagnosis Rate Evolution
• 13.4 Emerging Population Segments
• 13.5 Mental Health Infrastructure Impact
• 13.6 Strategic Recommendations
• 13.7 Long-Term Patient Population Outlook (2025-2045)

14. Appendix

• 14.1 Abbreviations
• 14.2 Glossary of Terms
• 14.3 References
• 14.4 List of Tables
• 14.5 List of Figures
• 14.6 Epidemiology Sources
• 14.7 Public Health Sources
• 14.8 Company Sources